Inhibikase Therapeutics's total assets for Q2 2025 were $88.85M, a decrease of -5.76% from the previous quarter. IKT total liabilities were $8.80M for the fiscal quarter, a 2.91% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.